Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Shiyu Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7663-629X; OpenAlex author ID A5077135287. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 14

  1. FGD5 regulates PGK1 ubiquitination to synergize with 2-deoxy-D-glucose in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-03943-1↗
  2. Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glycolysis in pancreatic cancer. First author DOI 10.1038/s41419-026-08958-w↗
  3. Sciellin inhibits senescence and promotes pancreatic cancer progress by activating the notch signaling pathway. Co-author DOI 10.1038/s41598-025-88265-0↗
  4. TRIM59/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway. Co-author DOI 10.1038/s41419-024-07324-y↗
  5. CD105+CAF-derived exosomes CircAMPK1 promotes pancreatic cancer progression by activating autophagy. Co-author DOI 10.1186/s40164-024-00533-3↗
  6. FOXQ1 promotes pancreatic cancer cell proliferation, tumor stemness, invasion and metastasis through regulation of LDHA-mediated aerobic glycolysis. Co-author DOI 10.1038/s41419-023-06207-y↗
  7. Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis. First author DOI 10.1038/s41419-022-04669-0↗
  8. FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic glycolysis. First author DOI 10.1038/s41419-022-05213-w↗
  9. RHBDL2 promotes the proliferation, migration, and invasion of pancreatic cancer by stabilizing the N1ICD via the OTUD7B and activating the Notch signaling path… Co-author DOI 10.1038/s41419-022-05379-3↗
  10. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis. Co-author DOI 10.1186/s13046-020-01687-8↗
  11. TRIM37 Mediates Chemoresistance and Maintenance of Stemness in Pancreatic Cancer Cells via Ubiquitination of PTEN and Activation of the AKT-GSK-3β-β-Catenin Si… Co-author DOI 10.3389/fonc.2020.554787↗
  12. MiR-137 promotes anoikis through modulating the AKT signaling pathways in Pancreatic Cancer. Co-author DOI 10.7150/jca.44037↗
  13. MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12. Co-author DOI 10.1186/s13046-019-1105-3↗
  14. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway. First author DOI 10.7150/thno.23259↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiwei He · 11 shared papers, 2019–2026 · strength 1.95
  2. Kun Cai · 7 shared papers, 2022–2026 · strength 1.57
  3. Cheng-Yi Sun · 5 shared papers, 2022–2026 · strength 1.01
  4. Chao Yu · 5 shared papers, 2018–2023 · strength 0.70
  5. Chengyi Sun · 5 shared papers, 2018–2020 · strength 0.58
  6. Changhao Wu · 2 shared papers, 2023–2025 · strength 0.49
  7. Chao Yu · 2 shared papers, 2022–2025 · strength 0.46
  8. Dijie Zheng · 2 shared papers, 2022 · strength 0.32
  9. Yanqing Liu · 2 shared papers, 2022 · strength 0.32
  10. Wenting Song · 1 shared paper, 2026 · strength 0.32
  11. Tianbao Wang · 1 shared paper, 2026 · strength 0.29
  12. Lin Li · 2 shared papers, 2020–2022 · strength 0.29
  13. Chengyi Sun · 1 shared paper, 2025 · strength 0.28
  14. Hui Liu · 1 shared paper, 2024 · strength 0.26
  15. Zhiwei He · 1 shared paper, 2024 · strength 0.26
  16. Xiushen Li · 1 shared paper, 2024 · strength 0.26
  17. Xiaowu Li · 1 shared paper, 2024 · strength 0.26
  18. Xundi Xu · 1 shared paper, 2024 · strength 0.22
  19. Yan Zhang · 1 shared paper, 2024 · strength 0.22
  20. Hao Hua · 1 shared paper, 2023 · strength 0.20
  21. Lin Li · 1 shared paper, 2022 · strength 0.17
  22. Lin Li · 1 shared paper, 2022 · strength 0.16
  23. Chao Yu · 1 shared paper, 2022 · strength 0.15
  24. Hao Zhang · 1 shared paper, 2020 · strength 0.13
  25. Li Lin · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.